# Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia

> **NCT04446806** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital of Soochow University** · enrollment: 100 (estimated)

## Conditions studied

- Safety and Efficacy

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT04446806
- **Lead sponsor:** The First Affiliated Hospital of Soochow University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-06-01
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-05-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2020-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04446806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04446806, "Prevention and Treatment of Differentiation Syndrome in Patients With Acute Promyelocytic Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04446806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*